OPKO Health, Inc. (NASDAQ:OPK) Shares Sold by Arizona State Retirement System

Arizona State Retirement System lessened its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 16.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 97,563 shares of the biotechnology company’s stock after selling 19,287 shares during the period. Arizona State Retirement System’s holdings in OPKO Health were worth $122,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Hennion & Walsh Asset Management Inc. raised its position in shares of OPKO Health by 11.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 776,020 shares of the biotechnology company’s stock worth $931,000 after purchasing an additional 79,525 shares during the period. Moseley Investment Management Inc. purchased a new position in OPKO Health in the 1st quarter worth about $41,000. Tidal Investments LLC acquired a new stake in OPKO Health during the 1st quarter worth about $239,000. Comerica Bank boosted its holdings in shares of OPKO Health by 125.0% in the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock worth $108,000 after buying an additional 50,000 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of OPKO Health in the first quarter worth about $26,000. 64.63% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other OPKO Health news, major shareholder Opko Health, Inc. sold 50,000 shares of OPKO Health stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $26.63, for a total value of $1,331,500.00. Following the completion of the sale, the insider now directly owns 3,508,603 shares in the company, valued at $93,434,097.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 736,644 shares of company stock valued at $23,874,134 in the last three months. Insiders own 47.26% of the company’s stock.

OPKO Health Stock Performance

Shares of OPK opened at $1.62 on Thursday. The company has a market capitalization of $1.13 billion, a PE ratio of -4.63 and a beta of 1.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. The company’s 50 day moving average price is $1.51 and its 200 day moving average price is $1.32. OPKO Health, Inc. has a 52 week low of $0.85 and a 52 week high of $1.75.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.08. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The business had revenue of $182.20 million for the quarter, compared to the consensus estimate of $184.70 million. During the same period in the prior year, the business posted ($0.03) earnings per share. OPKO Health’s revenue for the quarter was down 31.3% compared to the same quarter last year. Research analysts expect that OPKO Health, Inc. will post -0.29 EPS for the current fiscal year.

Analyst Ratings Changes

OPK has been the topic of several analyst reports. Barrington Research lifted their target price on shares of OPKO Health from $1.50 to $2.25 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Piper Sandler reiterated an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday. StockNews.com raised OPKO Health to a “sell” rating in a research report on Saturday, July 27th. Finally, HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.